tolerogenic dendritic cells loaded with myelin peptides / Clinical Foundation of Barcelona - LARVOL DELTA

Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B (clinicaltrials.gov) - P1; N=12; Active, not recruiting; Sponsor: Sara Varea; Recruiting ➔ Active, not recruiting

Enrollment closed • Biosimilar • Complement-mediated Rare Disorders • Immunology • Multiple Sclerosis • Neuromyelitis Optica Spectrum Disorder • Ophthalmology

Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B (clinicaltrials.gov) - P1; N=20; Completed; Sponsor: Sara Varea; Recruiting ➔ Completed

Clinical • Trial completion

Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B (clinicaltrials.gov) - P1; N=22; Recruiting; Sponsor: Sara Varea; Trial completion date: Dec 2018 ➔ Jun 2019; Trial primary completion date: Dec 2018 ➔ Jun 2019

Clinical • Trial completion date • Trial primary completion date